VIDEO: Photobiomodulation a promising tool for treating intermediate AMD
Key takeaways:
- The LIGHTSITE III study evaluated the use of photobiomodulation in dry age-related macular degeneration.
- At month 13, eyes treated with photobiomodulation had a visual acuity improvement of 5.4 letters.
NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Marion R. Munk, MD, PhD, discusses the 24-month analysis from the LIGHTSITE III study.
The study evaluated multiwavelength photobiomodulation (PBM) with the LumiThera Valeda light delivery system in 100 patients with dry age-related macular degeneration. Eyes treated with PBM had a visual acuity improvement of 5.4 letters at month 13. More than 60% of the eyes had a gain of more than five letters after 2 years.
“Photobiomodulation seems to be a very promising tool for the treatment of intermediate AMD,” Munk said.
Collapse
Munk MR, et al. LIGHTSITE III 24-month analysis: Evaluation of multiwavelength photobiomodulation in dry age-related macular degeneration using the LumiThera Valeda light delivery system. Presented at: Association for Research in Vision and Ophthalmology meeting; April 23-27, 2023; New Orleans.
Read more about